News & Events
News & Events Find out more about dates & events, the progress of our vaccine research and all the other interesting news on the topic. News Events More about us
History
History VEROVACCiNES spun off Martin-Luther-University Halle-Wittenberg in 2017. After validating the novel technology platform (Proof of Concept in several vaccine programs), we are pursuing development of our product pipeline and scaling up manufacturing. More about us „> 02/2022 Advisory board established „> 03/2021 K. lactis vaccines generate maternal antibodies Cooperation with European partner „> 07/2018 […]
Pipeline
Vaccine Programs Technology and products provide much-needed solutions to medical needs in animal health, including reducing antibiotic use. Product Pipeline Verovaccines‘ current product pipeline includes a number of vaccine projects, several of which have blockbuster potential. The pipeline of vaccine candidates documents the broad applicability of the proprietary K. lactis technology: Targeting 6 different pathogens […]
Innovation
Vaccine Technology VEROVACCiNES novel vaccines are based on recombinant strains of the yeast Kluyveromyces lactis, which stably express one or more antigens. This novel class of vaccines has significant advantages over conventional animal vaccines. https://verovaccines.com/wp-content/uploads/2022/06/the-milk-yeast-explained-3_1.mp4 HOW DOES THE TECHNOLOGY WORK? VEROVACCiNES novel vaccines are based on recombinant strains of the yeast Kluyveromyces lactis, which stably express one […]
Team
Team Verovaccines has a seasoned management team with expertise in animal health, virology, vaccine development, and corporate governance. The management is supported by an advisory board, with internationally experienced members from animal health, especially animal vaccines. Management Dr. Hanjo Hennemann CEO and co-founder Entrepreneur and molecular biologist contact me Prof. Dr. Sven-Erik Behrens CSO and […]